581 related articles for article (PubMed ID: 2825712)
21. Insulin activation of cyclic AMP phosphodiesterase in intact ureteral segments.
Weiss RM; Wheeler MA
J Pharmacol Exp Ther; 1988 Nov; 247(2):630-4. PubMed ID: 2846825
[TBL] [Abstract][Full Text] [Related]
22. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.
Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343
[TBL] [Abstract][Full Text] [Related]
23. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibition of cyclic AMP phosphodiesterase from various human tissues by milrinone, a potent cardiac bipyridine.
Ito M; Tanaka T; Saitoh M; Masuoka H; Nakano T; Hidaka H
Biochem Pharmacol; 1988 May; 37(10):2041-4. PubMed ID: 2837222
[TBL] [Abstract][Full Text] [Related]
25. Myofibrillar bound cyclic nucleotide phosphodiesterase in heart and skeletal muscle.
Worby A; Mensah LM; Murray KJ
Biochem Soc Trans; 1992 May; 20(2):129S. PubMed ID: 1327896
[No Abstract] [Full Text] [Related]
26. [Separation and investigation of the regulatory properties of two forms of cyclic nucleotide phosphodiesterase from rabbit heart--sensitive and insensitive to Ca-dependent regulator protein].
Tkachuk VA; Lazarevich VG; Men'shikov MIu; Severin SE
Biokhimiia; 1978 Sep; 43(9):1622-30. PubMed ID: 214170
[TBL] [Abstract][Full Text] [Related]
27. Regulation of cyclic nucleotide phosphodiesterase activity in rhesus fetal muscle.
Beatty CH; Herrington PT; Bocek RM
Biol Neonate; 1977; 32(1-2):33-42. PubMed ID: 198031
[TBL] [Abstract][Full Text] [Related]
28. Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone.
Earl CQ; Linden J; Weglicki WB
J Cardiovasc Pharmacol; 1986; 8(4):864-72. PubMed ID: 2427830
[TBL] [Abstract][Full Text] [Related]
29. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.
Lugnier C; Schini VB
Biochem Pharmacol; 1990 Jan; 39(1):75-84. PubMed ID: 2153383
[TBL] [Abstract][Full Text] [Related]
30. Evidence for convertible forms of soluble uterine cyclic nucleotide phosphodiesterase.
Strada SJ; Epstein PM; Gardner EA; Thompson WJ; Stancel GM
Biochim Biophys Acta; 1981 Sep; 661(1):12-20. PubMed ID: 6271215
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.
Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H
Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013
[TBL] [Abstract][Full Text] [Related]
32. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the low Km cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone.
Silver PJ; Lepore RE; O'Connor B; Lemp BM; Hamel LT; Bentley RG; Harris AL
J Pharmacol Exp Ther; 1988 Oct; 247(1):34-42. PubMed ID: 2845058
[TBL] [Abstract][Full Text] [Related]
34. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors.
Tang KM; Jang EK; Haslam RJ
Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608
[TBL] [Abstract][Full Text] [Related]
35. Bemoradan--a novel inhibitor of the rolipram-insensitive cyclic AMP phosphodiesterase from canine heart tissue.
Moore JB; Combs DW; Tobia AJ
Biochem Pharmacol; 1991 Jul; 42(3):679-83. PubMed ID: 1650219
[TBL] [Abstract][Full Text] [Related]
36. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine.
Souness JE; Brazdil R; Diocee BK; Jordan R
Br J Pharmacol; 1989 Nov; 98(3):725-34. PubMed ID: 2480168
[TBL] [Abstract][Full Text] [Related]
37. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
Torphy TJ; Zhou HL; Burman M; Huang LB
Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
[TBL] [Abstract][Full Text] [Related]
38. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
39. [Effect of several hormones on cyclic 3',5'-nucleotide phosphodiesterase in rat kidneys].
Iwase K
Nihon Naibunpi Gakkai Zasshi; 1983 Oct; 59(10):1678-91. PubMed ID: 6319206
[TBL] [Abstract][Full Text] [Related]
40. Chronotropic and inotropic actions of amrinone, carbazeran and isobutylmethyl xanthine: role of phosphodiesterase inhibition.
Shahid M; Rodger IW
Br J Pharmacol; 1989 Sep; 98(1):291-301. PubMed ID: 2478244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
